PIKfyve Inhibition Shows Promise Against Hepatitis E
Targeting this enzyme could lead to safer alternatives to current ribavirin-based hepatitis E treatments in the future.
Updated on Oct. 29, 2026 in Life Sciences
Live Poll
Should researchers prioritize repurposing existing drugs to treat new viral infections?
Researchers at Jilin University have identified the PIKfyve enzyme as a target to inhibit the hepatitis E virus. In laboratory models, the drug apilimod blocked the virus's entry process, demonstrating potential as a treatment alternative to ribavirin.
Why it matters
Current hepatitis E therapies rely on ribavirin, a drug often limited by significant toxicity and strict contraindications. Identifying a new cellular target could enable safer, more effective antiviral treatments for patients.
Silencing the PIKfyve enzyme reduced viral infection by approximately 40% in laboratory models. The treatment further inhibited the maturation of cathepsins B and L, which the virus requires for intracellular processes.
The players
Jilin University
A research institution in China that focuses on life sciences and biomedical innovation.
The details
PIKfyve is a lipid kinase—an enzyme that modifies lipids within cell membranes—that regulates the endolysosomal system, the cellular pathway responsible for processing and degrading material. The virus utilizes this system to transport its genome, but PIKfyve inhibition blocks the viral uncoating process by reducing the activity of cathepsins B and L, which are proteases or protein-degrading enzymes located in lysosomes. This prevents the virus from successfully delivering its genetic material into the cell.
Timeline
October 29, 2026: Findings regarding PIKfyve inhibition were published.
The Tech Race
This research shifts focus toward host-directed therapies, which aim to make cells inhospitable to viruses rather than attacking the virus directly. It marks a potential shift away from the traditional ribavirin standard used in clinical hepatitis E management.
This research is in the early stages and has not yet entered human clinical trials. Future patient availability depends on successful studies evaluating human safety, optimal treatment timing, and therapeutic dosing concentrations.
The takeaway
The study establishes a new mechanism for preventing hepatitis E entry into cells. Researchers must now determine whether apilimod can be safely administered to humans at the necessary antiviral concentrations.
Further reading
For more on emerging developments in molecular medicine, visit Life Sciences.
More information
Read the complete peer-reviewed research article for full methodology.
Source note: This article includes information reported by News-Medical.
Live Poll
Should researchers prioritize repurposing existing drugs to treat new viral infections?
